Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 12-month pregabalin adjunctive safety study in epilepsy
NL-OMON44084Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pregabalin in epilepsy, Focal Onset Epilepsy and Epilepsy with generalized tonic-clonic seizures alone (2 arms), sponsored by Pfizer. Primary endpoints: Adverse events, Physical examination and 7 more. Planned start Apr 2012; status: withdrawn.
02
Drugs
pregabalin
03
Conditions
epilepsyFocal Onset EpilepsyEpilepsy with generalized tonic-clonic seizures alone
Beyond the preview
Go deeper on NL-OMON44084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44084.